Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA9 | Q16790 | 4/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3682394 | 0.92 | KDM4E (0.57) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL2148841 | 0.92 | LMNA (0.57) | TSHRLMNACA1CA2CA9 | |
| Methyl 2,3-Dihydroxybenzoate SCHEMBL433982 | 0.89 | LMNA (0.70) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL13444406 | 0.88 | LMNA (0.53) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL334485 | 0.87 | ALDH1A1 (0.62) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL28236597 | 0.87 | LMNA (0.52) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL15906683 | 0.87 | LMNA (0.52) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL8875029 | 0.87 | TSHR (0.52) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL204668 | 0.86 | ALDH1A1 (0.69) | TSHRLMNACA1CA2CA9 | |
| SCHEMBL9639243 | 0.86 | TSHR (0.55) | TSHRLMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107935840-A | A kind of 4 Hydroxy M Phthalic Acid derivatives and synthetic method | 常州工程职业技术学院 | 2018-04-20 | — | — | CN | claimed |
| CN-105949047-A | Method for extracting 4-hydroxy-m-phthalic acid from wintergreen oil production waste slag | 东南大学 | 2016-09-21 | — | — | CN | claimed |
| US-9440891-B2 | Palladium-catalyzed decarbonylation of fatty acid anhydrides for the production of linear alpha olefins | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-09-13 | — | — | US | claimed |
| US-4833023-A | CONTAINING SOILD PLASTICIZER | MITSUBISHI PAPER MILLS, LTD. (JP) | 1989-05-23 | — | — | US | claimed |
| US-4745026-A | FINE PARTICLE SOLID PLASTICIZER | MITSUBISHI PAPER MILLS, LTD. (JP) | 1988-05-17 | — | — | US | claimed |
| EP-0132717-B1 | HEAT-SENSITIVE RECORD MATERIAL | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1987-04-22 | — | — | EP | claimed |
| US-4540999-A | HYDROXYPHTHALATE, CHROMOGEN | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1985-09-10 | — | — | US | claimed |
| EP-0132717-A1 | Heat-sensitive record material | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1985-02-13 | — | — | EP | claimed |
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | NEXYS THERAPEUTICS, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025045826-A1 | COMPOUNDS FOR ACTIVATION OF FGFR1 SIGNALING | THE CULTIVATED B. GMBH (DE) | 2025-03-06 | — | — | WO | disclosed |
| CN-116082181-B | Method for preparing 3-amino-5-ethoxy-benzoic acid | 爱斯特（成都）生物制药股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | NEXYS THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4472953-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | Nexys Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-5466553-A | Phenolic hydroxyl group-containing polyester binder resin | TOMOEGAWA PAPER CO., LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0617337-A2 | Toner for developing electrostatic image | TOMOEGAWA PAPER CO. LTD. (JP) | 1994-09-28 | — | — | EP | disclosed |
| US-4833023-A | CONTAINING SOILD PLASTICIZER | MITSUBISHI PAPER MILLS, LTD. (JP) | 1989-05-23 | — | — | US | disclosed |
| US-4745026-A | FINE PARTICLE SOLID PLASTICIZER | MITSUBISHI PAPER MILLS, LTD. (JP) | 1988-05-17 | — | — | US | disclosed |
| US-4442176-A | CHROMOGEN, HYDROXYPHTHALIC DIESTER OF SPECIFIED MELTING POINT | KAWASAKI KASEI CHEMICALS LTD. (JP) | 1984-04-10 | — | — | US | disclosed |
| US-3940543-A | BLOCK CO-POLYESTER | MITSUBISHI RAYON CO., LTD. (JA) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371408-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | TSHR 352/4885LMNA 4253/4885CA1 4417/4885 |
| US-20260022099-A1 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | AHR, NR1H4, CNR1 | TSHR 254/4885LMNA 3897/4885CA1 2945/4885 |
| US-12168646-B2 | Aryl hydrocarbon receptor agonists and uses thereof | AHR, ARNT, NR1H2 | TSHR 352/4885LMNA 4253/4885CA1 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.